RecruitingNot ApplicableNCT05413759

RhEumatoid Arthritis MEDIcation Adherence

Collaborative Pharmaceutical Care Initiated in Hospital and Continued in Primary Care to Improve Medication Adherence of Patients With Rheumatoid Arthritis


Sponsor

Hospices Civils de Lyon

Enrollment

200 participants

Start Date

Jun 28, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

Rheumatoid arthritis (RA) is a public health issue because of its frequency, its functional consequences, the risk of morbidity and mortality and the costs incurred. A collaborative multiprofessional intervention initiated during hospitalization and continued after hospital discharge (ambulatory care ) would improve medication adherence in RA and therefore the health status of patients. Main objective: To compare, 12 months after the index hospitalization or consultation, the impact of pharmaceutical care provided in multiprofessional collaboration (pharmacist-physician) on medication adherence to disease-modifying treatments of patients with RA compared to usual care without pharmaceutical care and specific multi-professional collaboration. Medication adherence to disease-modifying treatments will be assessed by the rate of coverage of disease-modifying treatments (or Medication Possession Ratio (MPR)). METHODOLOGY: Interventional, multicenter, controlled, randomized, open label study, comparing in parallel 2 groups of patients with rheumatoid arthritis initially hospitalized in a rheumatology department (pharmaceutical care provided in multiprofessional collaboration (pharmacist-physician), initiated in the hospital and continued after hospital discharge (ambulatory care) vs traditional follow-up.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating why some people with rheumatoid arthritis (RA) don't take their medications as prescribed (non-adherence). Researchers want to understand patterns of adherence to disease-modifying drugs and develop better support strategies. **You may be eligible if...** - You have been diagnosed with rheumatoid arthritis - You are 18 or older - You are currently hospitalized or attending a rheumatology consultation in France - You are taking RA medications including at least methotrexate, a JAK inhibitor (tsDMARD), or a subcutaneous biologic therapy (bDMARD) - You manage your own medications independently - You speak and understand French - You are covered by the French national health insurance system **You may NOT be eligible if...** - You cannot manage your own medications - You do not speak French - You are not affiliated with the French social security system Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERPharmaceutical care in multiprofessional collaboration

In addition to usual practices: medication reconciliation and pharmaceutical motivational interviews with patients (discharge, 2 \& 6 months). Objective of medication reconciliation (admission): to detect and resolve unintended medication discrepancies between home medication list and treatment and hospital admission medication orders. Objective of medication reconciliation (discharge): to obtain an exact list of medication, to explain the medication modifications during hospitalization. Objective of the Disease-Modifying Antirheumatic Drugs information interview (discharge): to provide information and to answer questions on the management of treatment, to deal with practical situations to assess patients' self-management skills. Objective of interviews (2 \& 6 months): to evaluate medications and their daily management, benefits and problems that patient may encounter, to assess the patient's ability to manage the treatment.


Locations(2)

Service de rhumatologie, Centre Hospitalier Lyon Sud, Groupement Hospitalier Sud, Hospices Civils de Lyon

Pierre-Bénite, Lyon, France

Service de rhumatologie et pathologie osseuse - Hôpital Edouard Herriot

Lyon, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05413759


Related Trials